Last reviewed · How we verify
Varied albuterol dose response
Albuterol is a beta-2 adrenergic agonist that stimulates beta-2 receptors on airway smooth muscle to cause bronchodilation.
Albuterol is a beta-2 adrenergic agonist that stimulates beta-2 receptors on airway smooth muscle to cause bronchodilation. Used for Asthma (acute bronchospasm relief and maintenance), Chronic obstructive pulmonary disease (COPD) (acute bronchospasm relief).
At a glance
| Generic name | Varied albuterol dose response |
|---|---|
| Also known as | Albuterol sulfate, Salbutamol, Proventil, ProAir, Ventolin |
| Sponsor | Oregon Health and Science University |
| Drug class | Beta-2 adrenergic agonist (short-acting bronchodilator) |
| Target | Beta-2 adrenergic receptor (ADRB2) |
| Modality | Small molecule |
| Therapeutic area | Respiratory/Pulmonology |
| Phase | FDA-approved |
Mechanism of action
Albuterol binds to and activates beta-2 adrenergic receptors on the smooth muscle of airways, triggering a cascade that increases intracellular cAMP and leads to smooth muscle relaxation and airway opening. This study appears to examine variable dose-response relationships in albuterol administration, likely investigating optimal dosing strategies or individual variability in patient response.
Approved indications
- Asthma (acute bronchospasm relief and maintenance)
- Chronic obstructive pulmonary disease (COPD) (acute bronchospasm relief)
Common side effects
- Tremor
- Headache
- Nervousness/anxiety
- Palpitations
- Tachycardia
- Muscle cramps
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Varied albuterol dose response CI brief — competitive landscape report
- Varied albuterol dose response updates RSS · CI watch RSS
- Oregon Health and Science University portfolio CI